nab-paclitaxel + pembrolizumab + pemetrexed

This drug is a combination therapy consisting of three agents used primarily for the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC). - **Nab-paclitaxel** is an albumin-bound formulation of paclitaxel, a microtubule inhibitor that disrupts mitosis in cancer cells. It offers improved delivery and reduced toxicity compared to solvent-based paclitaxel formulations. - **Pembrolizumab** is a monoclonal antibody immune checkpoint inhibitor targeting PD-1 (programmed death 1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 ligands and thereby enhancing anti-tumor immune response. - **Pemetrexed** is an antifolate chemotherapy agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, leading to inhibition of DNA and RNA synthesis in tumor cells. The combination leverages cytotoxic chemotherapy with immunotherapy to improve outcomes in metastatic or advanced NSCLC. Pembrolizumab plus pemetrexed with platinum chemotherapy has become a standard first-line regimen due to demonstrated survival benefits. Nab-paclitaxel combined with pemetrexed has shown feasibility and activity as well[1][4][5][6][10].

Other names

nanoparticle albumin-bound paclitaxel + pembrolizumab + pemetrexed